
DRTS
Alpha Tau Medical Ltd
$
2.520
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.525
Open
2.430
VWAP
2.39
Vol
96.52K
Mkt Cap
176.66M
Low
2.300
Amount
231.15K
EV/EBITDA(TTM)
--
Total Shares
69.80M
EV
121.92M
EV/OCF(TTM)
--
P/S(TTM)
--
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technol...Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
-0.127
+15.77%
--
--
-0.124
+12.99%
--
--
-0.123
+22.93%
Estimates Revision
The market is revisingNo Changethe revenue expectations for Alpha Tau Medical Ltd. (DRTS) for FY2025, with the revenue forecasts being adjusted by 0%over the past three months. During the same period, the stock price has changed by-20.50%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-0.37%
In Past 3 Month
Stock Price
Go Down

-20.50%
In Past 3 Month
3 Analyst Rating

190.87% Upside
Wall Street analysts forecast DRTS stock price to riseover the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.33USD with a low forecast of5.00USD and a high forecast of9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

190.87% Upside
Current: 2.520

Low
5.00
Averages
7.33
High
9.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2025-03-17
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-11-22
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-10-23
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-10-11
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-08-20
Reason
Piper Sandler
Jason Bednar
Buy
Reiterates
$7
2024-08-15
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-06-26
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-05-22
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-05-16
Reason
Valuation Metrics
The current forward P/E ratio for Alpha Tau Medical Ltd(DRTS.O) is -4.96, compared to its 5-year average forward P/E of -14.03. For a more detailed relative valuation and DCF analysis to assess Alpha Tau Medical Ltd 's fair value, click here.
Forward PE

N/A
5Y Average PE
-14.03
Current PE
-4.96
Overvalued PE
-1.72
Undervalued PE
-26.34
Forward EV/EBITDA

N/A
5Y Average EV/EBITDA
-3.91
Current EV/EBITDA
-2.89
Overvalued EV/EBITDA
0.33
Undervalued EV/EBITDA
-8.15
Forward PS

N/A
5Y Average PS
295.21
Current PS
537.06
Overvalued PS
956.96
Undervalued PS
-366.53
Financials
Annual
Quarterly
FY2024Q4
YoY :
+3.33%
-10.27M
Operating Profit
FY2024Q4
YoY :
+28.66%
-9.48M
Net Income after Tax
FY2024Q4
YoY :
+27.27%
-0.14
EPS - Diluted
FY2022Q2
YoY :
+221.47%
-9.12M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DRTS News & Events
Events Timeline
2025-04-02 (ET)
2025-04-02
08:31:33
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM

2025-02-24 (ET)
2025-02-24
08:45:17
Alpha Tau receives MDSAP certification

2025-01-27 (ET)
2025-01-27
08:09:14
Alpha Tau announces interim data from pembrolizumab combination trial

2025-01-27
08:07:05
Alpha Tau receives IDE from FDA for study evaluating Alpha DaRT, chemo combo

2025-01-27
08:05:59
Alpha Tau shares interim data across multiple clinical trials at R&D Update Day

2024-12-17 (ET)
2024-12-17
08:08:58
Alpha Tau appoints Nester to its board of directors

2024-10-21 (ET)
2024-10-21
08:34:11
Alpha Tau announces acceptance into FDA's TPLC TAP Pilot

2024-10-10 (ET)
2024-10-10
08:36:26
Alpha Tau treats first patient with recurrent lung cancer

2024-09-20 (ET)
2024-09-20
08:34:30
Alpha Tau announces FDA approval of IDE to initiate study of Alpha DaRT

News
9.0
02-24NewsfilterAlpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
9.0
01-27NewsfilterAlpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
1.0
2024-12-18NewsfilterAlpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
5.0
2024-12-17NewsfilterAlpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
4.0
2024-12-12NASDAQ.COMValidea Kenneth Fisher Strategy Daily Upgrade Report - 12/12/2024
1.0
2024-12-11NewsfilterAlpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
1.0
2024-12-06NewsfilterAlpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium
9.5
2024-11-19NewsfilterAlpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
4.0
2024-10-23BenzingaHC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
9.0
2024-10-21NewsfilterAlpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
4.0
2024-10-11BenzingaHC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
9.0
2024-10-10NewsfilterAlpha Tau Treats First Patient with Recurrent Lung Cancer
1.0
2024-08-22NewsfilterAlpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
4.0
2024-08-15BenzingaPiper Sandler Reiterates Overweight on Alpha Tau Medical, Maintains $7 Price Target
9.0
2024-08-15Business InsiderDRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024
1.6
2024-06-25NewsfilterAlpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
-.-
2024-05-21newsfilterAlpha Tau to Present at the Jefferies Global Healthcare Conference
-.-
2024-05-21Business InsiderDRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024
-.-
2024-05-06newsfilterAlpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
1.0
1970-01-01NewsfilterSidoti Events, LLC's Virtual September Small-Cap Conference
People Also Watch

SII
Sprott Inc
40.620
USD
-6.53%

ASPN
Aspen Aerogels Inc
5.470
USD
-2.67%

REAL
RealReal Inc
5.290
USD
+0.38%

INOD
Innodata Inc
29.970
USD
-10.08%

KFRC
Kforce Inc
46.750
USD
-1.04%

LMB
Limbach Holdings Inc
69.300
USD
-5.30%

CMCO
Columbus McKinnon Corp
14.550
USD
-1.09%

TH
Target Hospitality Corp
6.550
USD
-2.53%

FWRG
First Watch Restaurant Group Inc
16.330
USD
-4.95%

CSWC
Capital Southwest Corp
19.780
USD
-9.14%
FAQ

What is Alpha Tau Medical Ltd (DRTS) stock price today?
The current price of DRTS is 2.52 USD — it hasincreased1.61 % in the last trading day.

What is Alpha Tau Medical Ltd (DRTS)'s business?

What is the price predicton of DRTS Stock?

What is Alpha Tau Medical Ltd (DRTS)'s revenue for the last quarter?

What is Alpha Tau Medical Ltd (DRTS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Alpha Tau Medical Ltd (DRTS)'s fundamentals?

How many employees does Alpha Tau Medical Ltd (DRTS). have?
